Anthony Vendetti, an analyst from Maxim Group, reiterated the Buy rating on Daxor. The associated price target is $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anthony Vendetti has given his Buy rating due to a combination of factors, primarily driven by the recent FDA 510(k) clearance of Daxor’s next-generation blood volume analyzer (BVA). This approval is seen as a significant milestone, as the new device offers several advancements over its predecessor, including faster processing times, enhanced portability, and improved ease of use. These improvements are expected to facilitate broader clinical adoption and utilization across various healthcare settings, which should support Daxor’s topline growth.
Additionally, recent studies and presentations have highlighted the precision and clinical benefits of Daxor’s BVA technology, particularly in managing heart failure patients. The compelling valuation, supported by a 10-year discounted cash flow analysis, further strengthens the Buy recommendation. Vendetti anticipates that the adoption of Daxor’s BVA-100 could become more widespread, potentially elevating it to a standard-of-care status, which would provide further upside to the stock’s price target.